I-Tagrisso: ukunyanga umhlaza wemiphunga

Umxholo

• Ixabiso
• Yenzelwe ntoni
• Kusetyenziswa kwanjani
• Iziphumo ebezingalindelekanga ezinokwenzeka
• Ngubani ongafanele asebenzise

I-Tagrisso yinyango elwa nomhlaza esetyenziselwa ukunyanga umhlaza wamaphaphu ongaqhelekanga.

Esi sixhobo siqulethe u-Osimertinib, into ethintela ukusebenza kwe-EGFR, isamkeli somhlaza esilawula ukukhula nokuphindaphindeka. Ke, iiseli zethumba azikwazi ukukhula ngokufanelekileyo kwaye isantya sophuhliso lomhlaza sincipha, siphucula iziphumo zolunye unyango, ezinje ngekhemotherapy.

I-Tagrisso iveliswa ziilebhu ze-AstraZeneca kwaye zingathengwa ezikhemisti ngommiselo, ngohlobo lweepilisi ezingama-40 okanye ezingama-80 mg.

Ixabiso

Nangona eli chiza sele livunyiwe yi-Anvisa eBrazil, alikathengiswa.

Yenzelwe ntoni

I-Tagrisso ibonakalisiwe kunyango lwabantu abadala abanomhlaza wesifo somhlaza wamaphaphu ongekho mncinci okanye imastastase enesimo esihle se-T790M kwi-EGFR receptor gene.

Kusetyenziswa kwanjani

Unyango ngeliyeza kufuneka lihlale likhokelwa ngumhlaza, ngokwenqanaba lokukhula komhlaza.

Nangona kunjalo, idosi ekhuthazwayo yipilisi ye-1 80 mg okanye ithebhulethi eyi-2 40 mg kanye ngemini.

Iziphumo ebezingalindelekanga ezinokwenzeka

Ukusetyenziswa kweTagrisso kunokubangela ezinye iziphumo ebezingalindelekanga ezinjengorhudo, iintlungu zesisu, imihlathi kunye nolusu olurhawuzayo kunye notshintsho kuvavanyo lwegazi, ngakumbi kwinani leeplatelets, ii-leukocytes kunye nee-neutrophils.

Ngubani ongafanele asebenzise

I-Tagrisso akufuneki isetyenziswe ngabafazi abakhulelweyo okanye abancancisayo, kunye nabantu abangadibaniyo nakwezinye izinto kwifomula. Ukongeza, awufanele uthathe i-wort yaseSt.John ngexesha lonyango ngale ndlela.